This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.35% per year. These returns cover a period from January 1, 1988 through December 2, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
by Ekta Bagri
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GSKPositive Net Change MRKNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
REGNNegative Net Change IONSPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing genomics pharmaceuticals
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
by Zacks Equity Research
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.
RAREPositive Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
by Zacks Equity Research
Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.
VRTXPositive Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
by Zacks Equity Research
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
NVONegative Net Change LLYPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
ALNYPositive Net Change EXELNegative Net Change SRPTNegative Net Change ADMANegative Net Change
biotechnology biotechs gene-therapy immuno-therapy medical pharmaceuticals
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
by Zacks Equity Research
The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft versus host disease. Shares rise.
NVSPositive Net Change INCYPositive Net Change MESONegative Net Change SPRONegative Net Change
biotechs
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
by Zacks Equity Research
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
CTMXNegative Net Change SPRONegative Net Change KRYSPositive Net Change CSTLPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
by Zacks Equity Research
Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market.
ENZPositive Net Change
biotechnology biotechs earnings medical
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
by Zacks Equity Research
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
RHHBYPositive Net Change SRPTNegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Here's Why VKTX Stock Plummeted 18% on Wednesday
by Zacks Equity Research
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.
NVONegative Net Change MRKNegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
by Zacks Equity Research
Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
REGNNegative Net Change BAYRYNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
by Zacks Equity Research
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.
GILDPositive Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
by Zacks Equity Research
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
REGNNegative Net Change GSKPositive Net Change GILDPositive Net Change ANABNegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
by Zacks Equity Research
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
SNYPositive Net Change JNJPositive Net Change TEVAPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
by Zacks Equity Research
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
GSKPositive Net Change JNJPositive Net Change PFEPositive Net Change ANABNegative Net Change
biotechs
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
by Zacks Equity Research
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
NVONegative Net Change LLYPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
by Zacks Equity Research
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change EWTXNegative Net Change
biotechs medical
Merck Ends Development of Two Experimental Cancer Drugs
by Zacks Equity Research
MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies.
MRKNegative Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
by Ekta Bagri
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
SRPTNegative Net Change VYGRPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
by Zacks Equity Research
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
GSKPositive Net Change GILDPositive Net Change MRUSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
by Zacks Equity Research
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
REGNNegative Net Change RHHBYPositive Net Change BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
by Zacks Equity Research
The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.
MRKNegative Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
by Zacks Equity Research
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
EDITNegative Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
by Zacks Equity Research
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
ABBVPositive Net Change CTMXNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals